Feb. 4, 2008
Omicron Biochemicals, Inc. and Oligo Factory announced an agreement today for the manufacture, sale and distribution of stable isotopically labeled oligodeoxyribonucleotides (DNA). The companies will offer labeled oligos with 13C, 15N, and/or 2H isotopes that are both site and residue specific. In late 2008 the companies plan to offer an equivalent service for oligoribonucleotides (RNA).
The agreement blends the strengths of both companies, with Omicron’s expertise in isotope labeling technology and the Oligo Factor specializing in milligram to gram scale synthesis and purification of oligonucleotides.
Dr. Anthony Serianni, CEO of Omicron, said, “We receive requests regularly for oligonucleotides labeled with stable isotopes but have been unable to offer a comprehensive service until this agreement with the Oligo Factor. We are pleased to be able to now satisfy our customers’ needs and broaden the basis of our business.”
Tim McGrath, CEO of the Oligo Factory, concurred and added, “Being able to partner with Omicron Biochemicals, which has a depth of experience in this very specialized market, is a boon to our customers and our business.”
About Omicron Biochemicals: Omicron Biochemicals is located in South Bend, Indiana and has been in operation since 1982. The company develops and improves methods to introduce stable isotopes into biologically important compounds. The company specializes in the synthesis of labeled nucleosides, carbohydrates and their derivatives.
About Oligo Factory: Oligo Factory operates out of its facility in Holliston, MA. The company was formed in 2006 and focuses its efforts on medium scale synthesis and purification of DNA, RNA, chimeras and their modifications.
For more information contact:
Shikai Zhao – Omicron Biochemicals – 574-287-6910
Web: omicronbio.com
Email: omicron@omicronbio.com
Tim McGrath – Oligo Factory – 508-275-3561
Web: oligofactory.com
Email: info@oligofactory.com